These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 37038634)

  • 1. Cardiac amyloidosis: A survey of current awareness, diagnostic modalities, treatment practices, and clinical challenges among cardiologists in selected Middle Eastern countries.
    Mohty D; Nasr S; Ragy H; Farhan HA; Fadel B; Alayary I; Ghoubar M
    Clin Cardiol; 2023 Jun; 46(6):648-655. PubMed ID: 37038634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing knowledge and awareness of transthyretin cardiac amyloidosis and shared decision-making among cardiology team members in Colorado, USA via an online educational initiative.
    Ismailov RM; Lerut J; Aceña Á; Khasanova ZD
    Hosp Pract (1995); 2022 Feb; 50(1):37-41. PubMed ID: 34879213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of Amyloidosis: A Survey of Current Awareness and Clinical Challenges Among Cardiologists in Switzerland.
    Mircsof D
    Cardiol Ther; 2020 Jun; 9(1):127-138. PubMed ID: 31960349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
    Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
    Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
    Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
    JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
    Debonnaire P; Claeys M; De Smet M; Trenson S; Lycke M; Demeester C; Van Droogenbroeck J; De Vriese AS; Verhoeven K; Vantomme N; Van Meirhaeghe J; Willandt B; Lambert M; de Paepe P; Delanote J; De Geeter F; Tavernier R
    Acta Cardiol; 2022 Nov; 77(9):791-804. PubMed ID: 34565298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Challenges of Cardiac Amyloidosis Awareness among Romanian Cardiologists.
    Adam R; Neculae G; Stan C; Jurcut R
    Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34066384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates.
    Nativi-Nicolau J; Sarswat N; Fajardo J; Finkel M; Abdulsattar Y; Castaño A; Klein L; Haddad-Angulo A
    Clin Med Insights Cardiol; 2021; 15():11795468211015230. PubMed ID: 34104028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
    Vaishnav J; Brown E; Sharma K
    Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society.
    Grzybowski J; Podolec P; Holcman K; Gawor-Prokopczyk M; Jankowska E; Kostkiewicz M; Dąbrowska-Kugacka A; Lipowska M; Mazurkiewicz Ł; Rajtar-Salwa R; Rubiś P; Straburzyńska-Migaj E; Szczygieł J; Mitkowski P
    Kardiol Pol; 2023; 81(11):1167-1185. PubMed ID: 37768101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
    Yamamoto H; Yokochi T
    ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
    Nativi-Nicolau JN; Karam C; Khella S; Maurer MS
    Heart Fail Rev; 2022 May; 27(3):785-793. PubMed ID: 33609196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries.
    Lauppe R; Liseth Hansen J; Fornwall A; Johansson K; Rozenbaum MH; Strand AM; Väkeväinen M; Kuusisto J; Gude E; Smith JG; Gustafsson F
    ESC Heart Fail; 2022 Aug; 9(4):2528-2537. PubMed ID: 35560802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective.
    Apostolou EA; Fontrier AM; Efthimiadis GK; Kastritis E; Parissis J; Kanavos P
    Hellenic J Cardiol; 2023; 73():73-80. PubMed ID: 37201632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
    Smiley DA; Rodriguez CM; Maurer MS
    Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM; Maurer MS
    Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.